Role of sublingual asenapine in treatment of schizophrenia

Leslie CitromeNew York University School of Medicine, Department of Psychiatry, New York, NY, USAAbstract: Asenapine tablets are a new option for the treatment of schizophrenia. Sublingual administration is essential because bioavailability if ingested is less than 2%. Efficacy is supported by acute...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Citrome L
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/589f49acb84f4d5fa42f9e3e44a0e5f2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:589f49acb84f4d5fa42f9e3e44a0e5f2
record_format	dspace
spelling	oai:doaj.org-article:589f49acb84f4d5fa42f9e3e44a0e5f22021-12-02T01:40:40ZRole of sublingual asenapine in treatment of schizophrenia1176-63281178-2021https://doaj.org/article/589f49acb84f4d5fa42f9e3e44a0e5f22011-05-01T00:00:00Zhttp://www.dovepress.com/role-of-sublingual-asenapine-in-treatment-of-schizophrenia-a7535https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Leslie CitromeNew York University School of Medicine, Department of Psychiatry, New York, NY, USAAbstract: Asenapine tablets are a new option for the treatment of schizophrenia. Sublingual administration is essential because bioavailability if ingested is less than 2%. Efficacy is supported by acute and long-term randomized controlled studies conducted by the manufacturer, with asenapine 5 mg twice daily evidencing superiority over placebo in six-week studies of acute schizophrenia, and flexibly-dosed asenapine (modal dose 10 mg twice daily) superior to placebo in a 26-week maintenance of response study. Tolerability advantages over some second-generation antipsychotics, such as olanzapine, include a relatively favorable weight and metabolic profile, as demonstrated in a 52-week randomized, head-to-head, double-blind clinical trial. Although dose-related extrapyramidal symptoms and akathisia can be present, the frequency of these effects is lower than that for haloperidol and risperidone. Somnolence may also occur, and appears to be somewhat dose-dependent when examining rates of this among patients receiving asenapine for schizophrenia and bipolar disorder. Prolactin elevation can occur, but at a rate lower than that observed for haloperidol or risperidone. Unique to asenapine is the possibility of oral hypoesthesia, occurring in about 5% of participants in the clinical trials. Obstacles to the use of asenapine are the recommendations for twice-daily dosing and the need to avoid food or liquids for 10 minutes after administration, although the bioavailability is only minimally reduced if food or liquids are avoided for only two minutes.Keywords: antipsychotic, asenapine, clinical trials, schizophreniaCitrome LDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2011, Iss Issue 1, Pp 325-339 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Citrome L Role of sublingual asenapine in treatment of schizophrenia
description	Leslie CitromeNew York University School of Medicine, Department of Psychiatry, New York, NY, USAAbstract: Asenapine tablets are a new option for the treatment of schizophrenia. Sublingual administration is essential because bioavailability if ingested is less than 2%. Efficacy is supported by acute and long-term randomized controlled studies conducted by the manufacturer, with asenapine 5 mg twice daily evidencing superiority over placebo in six-week studies of acute schizophrenia, and flexibly-dosed asenapine (modal dose 10 mg twice daily) superior to placebo in a 26-week maintenance of response study. Tolerability advantages over some second-generation antipsychotics, such as olanzapine, include a relatively favorable weight and metabolic profile, as demonstrated in a 52-week randomized, head-to-head, double-blind clinical trial. Although dose-related extrapyramidal symptoms and akathisia can be present, the frequency of these effects is lower than that for haloperidol and risperidone. Somnolence may also occur, and appears to be somewhat dose-dependent when examining rates of this among patients receiving asenapine for schizophrenia and bipolar disorder. Prolactin elevation can occur, but at a rate lower than that observed for haloperidol or risperidone. Unique to asenapine is the possibility of oral hypoesthesia, occurring in about 5% of participants in the clinical trials. Obstacles to the use of asenapine are the recommendations for twice-daily dosing and the need to avoid food or liquids for 10 minutes after administration, although the bioavailability is only minimally reduced if food or liquids are avoided for only two minutes.Keywords: antipsychotic, asenapine, clinical trials, schizophrenia
format	article
author	Citrome L
author_facet	Citrome L
author_sort	Citrome L
title	Role of sublingual asenapine in treatment of schizophrenia
title_short	Role of sublingual asenapine in treatment of schizophrenia
title_full	Role of sublingual asenapine in treatment of schizophrenia
title_fullStr	Role of sublingual asenapine in treatment of schizophrenia
title_full_unstemmed	Role of sublingual asenapine in treatment of schizophrenia
title_sort	role of sublingual asenapine in treatment of schizophrenia
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/589f49acb84f4d5fa42f9e3e44a0e5f2
work_keys_str_mv	AT citromel roleofsublingualasenapineintreatmentofschizophrenia
_version_	1718402959045296128

Role of sublingual asenapine in treatment of schizophrenia

Ejemplares similares